000			03287nam a22005657a 4500
008			130913s20132013 xxu||||| |||| 00| 0 eng dOvid Technologies
022			_a0732-8893
040			_aOvid MEDLINE(R)
099			_a23357290
245			_aAssessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
251			_aDiagnostic Microbiology & Infectious Disease. 75(3):298-303, 2013 Mar.
252			_aDiagn Microbiol Infect Dis. 75(3):298-303, 2013 Mar.
253			_aDiagnostic microbiology and infectious disease
260			_c2013
260			_fFY2013
266			_d2013-09-17
520			_aCeftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright 2013 Elsevier Inc. All rights reserved.
546			_aEnglish
650			_a*Anti-Bacterial Agents/tu [Therapeutic Use]
650			_a*Cephalosporins/tu [Therapeutic Use]
650			_a*Community-Acquired Infections/dt [Drug Therapy]
650			_a*Pneumonia, Pneumococcal/dt [Drug Therapy]
650			_aAged
650			_aAged, 80 and over
650			_aBacteremia/dt [Drug Therapy]
650			_aBacteremia/mi [Microbiology]
650			_aCeftriaxone/tu [Therapeutic Use]
650			_aCommunity-Acquired Infections/mi [Microbiology]
650			_aFemale
650			_aHumans
650			_aLogistic Models
650			_aMale
650			_aMicrobial Sensitivity Tests
650			_aMiddle Aged
650			_aOdds Ratio
650			_aPneumonia, Pneumococcal/mi [Microbiology]
650			_aRetrospective Studies
650			_aTreatment Outcome
651			_aMedStar Washington Hospital Center
656			_aMedicine/Pulmonary-Critical Care
657			_aClinical Trial, Phase III
657			_aJournal Article
657			_aMulticenter Study
657			_aRandomized Controlled Trial
657			_aResearch Support, Non-U.S. Gov't
700			_aShorr, Andrew F
790			_aEckburg PB, Friedland HD, Kollef M, Llorens L, Shorr AF
856			_uhttp://dx.doi.org/10.1016/j.diagmicrobio.2012.12.002 _zhttp://dx.doi.org/10.1016/j.diagmicrobio.2012.12.002
942			_cART _dArticle
999			_c1279 _d1279